Labcorp Holdings saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 78 to 82.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary rating identifies share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves.
Labcorp Holdings is in a buy range after climbing above a 258.59 buy point in a consolidation. The proper buying range extends to 5% above the initial entry. Once a stock hits that benchmark, it's best to hold off investing and wait for it to set up another buying opportunity.
Labcorp Holdings posted 4% EPS growth in the latest quarterly report. Sales rose 5%.
The company holds the No. 9 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Progyny and Stevanato Group are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
